Bonti has commenced dosing in its LANTERN-2 clinical trial, a Phase II study designed to evaluate the safety and efficacy of EB-001A for the treatment of patients with focal muscle pain.

LANTERN-2 is part of Bonti’s Long-Acting Neuro Toxin-E Relief, Non-opioid (LANTERN) clinical trial programme.

The trial includes patients undergoing elective abdominoplasty (tummy tuck) surgery.

Its dose selection phase is based on positive safety results from a recently completed LANTERN-1 clinical trial, the first of the LANTERN programme.

The trial includes a single intra-operative administration of EB-001T IM injection into the rectus abdominis (RA) muscle in the enrolled patients undergoing abdominoplasty with plication of the RA sheath.

"EB-001T has the potential to be an effective locally acting pain treatment that addresses a root cause of pain."

Primary endpoint of the trial is reduction of post-operative pain at rest as measured by the Numeric Pain Rating Scale (NPRS) over the first 96 hours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its secondary endpoints feature NPRS during activity and patient use of rescue medications, including opioids, to address unrelieved pain.

Topline results from the trial are expected to be available in the fourth quarter of this year.

Bonti CEO and co-founder Fauad Hasan said: “EB-001T has the potential to be an effective locally acting pain treatment that addresses a root cause of pain by decreasing muscle hyperactivity and spasms following surgery and in non-surgical cases.

“EB-001T may help healthcare providers and patients reduce the use of opioids, with their associated side effects and risk of addiction. We continue to press ahead toward the objective of establishing EB-001T as a long-acting, non-opioid solution for the treatment of focal muscle pain.”

EB-001A is derived from botulinum neurotoxin serotype E (BoNT/E) and can have a differentiated clinical profile with a faster onset of efficacy and a shorter duration of activity than botulinum neurotoxin serotype A (BoNT/A) products.